Successful trial of dengue vaccine 'TV-005' completed in Bangladesh
Dhaka, Sept 29: For the first time in Bangladesh, researchers from the International Centre for Diarrhea Research, Bangladesh (ICDDR,B) and the Lerner College of Medicine of the University of Vermont (UVM), USA, have completed research on a suitable vaccine against all four types of dengue virus.
For the first time in dengue-prone Bangladesh, researchers from the International Center for Disease Research, Bangladesh (ICDDR,B) and the Lerner College of Medicine at the University of Vermont (UVM), USA, have developed a tetravalent dengue vaccine, effective against all four types of the dengue virus, an ICDDR,B news release said on Thursday, September 28. Completed research on vaccines.
Studies evaluating the single-dose dengue vaccine TV-005 show that it is safe for use in children and adults and is able to induce immunity. The results of the study were recently published in 'The Lancet Infectious Diseases Journal'.
Dengue is a mosquito-borne virus that has become a major problem worldwide, especially in tropical regions. Mild symptoms of dengue include fever and bone pain, and severe cases include shock, bleeding and, in many cases, death. Generally four dengue types (Den 1, 2, 3, 4) or serotypes may be active singly or in combination.
According to the ICDDR, B, any serotype can make a person sick. However, a second infection with a different serotype increases the risk of serious illness. Bangladesh is one of the most densely populated (1,119 people/sq km) countries in the world, home to about 17 crore people. Dengue has been endemic in Bangladesh for more than 20 years, but in recent times its size and severity have increased at an alarming rate. This year's ongoing dengue outbreak is the most severe so far and has had a devastating impact on Dhaka's health system. 958 people have died this year across the country. From January 1 to September 27 of this year, 1 lakh 96 thousand 831 people were infected with dengue.